AKYA Key Statistics, Chart & Performance
The current stock price of AKYA is 1.29 USD. In the past month the price increased by 13.16%. In the past year, price decreased by -44.16%.
AKYA Latest News, Press Relases and Analysis
AKYA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.16 | 221.31B | ||
| DHR | DANAHER CORP | 29.44 | 162.53B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 181.97 | 55.22B | ||
| A | AGILENT TECHNOLOGIES INC | 28.18 | 43.55B | ||
| IQV | IQVIA HOLDINGS INC | 19.62 | 38.79B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.14 | 30.28B | ||
| WAT | WATERS CORP | 31.46 | 23.78B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.75 | 19.70B | ||
| ILMN | ILLUMINA INC | 28.89 | 19.36B | ||
| MEDP | MEDPACE HOLDINGS INC | 43.25 | 17.42B | ||
| TEM | TEMPUS AI INC | N/A | 13.21B | ||
| RVTY | REVVITY INC | 21 | 11.67B |
Related stock screener links
About AKYA
Company Profile
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2021-04-16. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
Company Info
AKOYA BIOSCIENCES INC
100 Campus Drive, 6th Floor
Marlborough MASSACHUSETTS US
CEO: Brian McKelligon
Employees: 330
Phone: 18558968401
AKOYA BIOSCIENCES INC / AKYA FAQ
Can you describe the business of AKOYA BIOSCIENCES INC?
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company went IPO on 2021-04-16. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.
Can you provide the latest stock price for AKOYA BIOSCIENCES INC?
The current stock price of AKYA is 1.29 USD. The price decreased by -5.15% in the last trading session.
Does AKOYA BIOSCIENCES INC pay dividends?
AKYA does not pay a dividend.
What is the ChartMill rating of AKOYA BIOSCIENCES INC stock?
AKYA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is AKYA stock listed?
AKYA stock is listed on the Nasdaq exchange.
What is the employee count for AKYA stock?
AKOYA BIOSCIENCES INC (AKYA) currently has 330 employees.
AKYA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AKYA. When comparing the yearly performance of all stocks, AKYA is a bad performer in the overall market: 90.51% of all stocks are doing better.
AKYA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AKYA. AKYA may be in some trouble as it scores bad on both profitability and health.
AKYA Financial Highlights
Over the last trailing twelve months AKYA reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS increased by 31.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AKYA Forecast & Estimates
11 analysts have analysed AKYA and the average price target is 1.45 USD. This implies a price increase of 12.08% is expected in the next year compared to the current price of 1.29.
For the next year, analysts expect an EPS growth of 38.62% and a revenue growth 4.99% for AKYA